Compare ENTA & GCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENTA | GCO |
|---|---|---|
| Founded | 1995 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.5M | 421.8M |
| IPO Year | 2012 | 1994 |
| Metric | ENTA | GCO |
|---|---|---|
| Price | $11.37 | $36.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | $21.83 | ★ $39.67 |
| AVG Volume (30 Days) | ★ 242.2K | 96.0K |
| Earning Date | 11-16-2026 | 12-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.93 | ★ 171.84 |
| EPS | N/A | ★ N/A |
| Revenue | $102,814,000.00 | ★ $2,606,898,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 16.48 | 13.71 |
| 52 Week Low | $10.20 | $21.93 |
| 52 Week High | $17.15 | $43.60 |
| Indicator | ENTA | GCO |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 56.52 |
| Support Level | $10.86 | $31.83 |
| Resistance Level | $13.95 | $38.33 |
| Average True Range (ATR) | 0.64 | 1.28 |
| MACD | -0.08 | 0.15 |
| Stochastic Oscillator | 28.14 | 66.05 |
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Genesco Inc sells footwear, headwear, sports apparel, and accessories. It has four reportable business segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass. The brands of the company are: Journeys; Journeys Kidz; Little Burgundy; Schuh; Johnston & Murphy; and Genesco Brands Group.